Key result
Elevated plasma NT-proBNP was a strong independent predictor of 30-day major adverse clinical outcomes in patients with ST-segment elevated acute myocardial infarction undergoing primary PCI.
Why the study?
Does elevated NT-proBNP predict 30-day major adverse clinical outcomes in patients with ST-segment elevated AMI undergoing primary PCI?
Cohort (n=242)
No
Does elevated NT-proBNP predict 30-day major adverse clinical outcomes in patients with ST-segment elevated AMI undergoing primary PCI?
Answers are grounded in this paper and cite their sources.
Elevated plasma NT-proBNP on admission is a strong independent predictor of 30-day major adverse clinical outcomes and mortality in patients with STEMI undergoing primary PCI.
BACKGROUND: Increased levels of N-terminal pro-brain natiuretic peptide (NT-proBNP) are now recognized as a new and useful biochemical marker that is predictive of clinical outcomes in patients with congestive heart failure (CHF). However, an association between an increased circulating level of this biomarker and clinical outcomes in patients following acute myocardial infarction (AMI) has not been fully delineated. Thus, the purpose of this study was to test whether NT-proBNP can predict prognosis in patients following ST-segment elevated AMI. METHODS AND RESULTS: A prospective cohort study of 242 consecutive patients with ST-segment elevated AMI of onset <12 h who underwent primary percutaneous coronary intervention (PCI) was conducted. Blood samples for plasma concentration of NT-proBNP were collected following vascular puncture. Univariate analysis demonstrated that the 30-day composite major adverse clinical outcomes (MACO) [advanced Killip score > or =3, functional class > or =3 of CHF and 30-day mortality] were strongly associated with elevated NT-proBNP (>243 pg/ml) (p<0.0001), unsuccessful reperfusion (final thrombolysis in myocardial infarction flow < or =2) (p<0.0001), left ventricular ejection fraction (LVEF) <45% (p<0.0001), diabetes mellitus (DM) (p=0.0004) and multivessel disease (p=0.0005). Multiple stepwise logistic regression analysis demonstrated that elevation of NT-proBNP (p=0.0002), LVEF < 45% (p=0.0003), DM (p=0.0007), unsuccessful reperfusion (p=0.006), and age (> or =70 years) (p=0.031) are independent predictors of 30-day MACO. Additionally, elevation of NT-proBNP, together with advanced Killip score and unsuccessful reperfusion, are significant independent predictors of increased 30-day mortality (all p values <0.005). CONCLUSION: Increased NT-proBNP level was the most independent predictor of 30-day MACO in patients with ST-segment elevated AMI undergoing primary PCI.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2006) conducted a cohort in ST-segment elevated acute myocardial infarction (AMI) (n=242). Elevated NT-proBNP (>243 pg/ml) vs. NT-proBNP ≤243 pg/ml was evaluated on 30-day composite major adverse clinical outcomes (MACO) including advanced Killip score ≥3, advanced CHF, or 30-day death (OR 3.59, 95% CI 1.85-7.00, p=0.0002). Elevated plasma NT-proBNP was a strong independent predictor of 30-day major adverse clinical outcomes in patients with ST-segment elevated acute myocardial infarction undergoing primary PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: